Thymidine Kinas
from web site
Thymidine Kinase 2 Deficiency (TK2D) is a rare genetic disorder caused by TK2 mutations, resulting in mitochondrial DNA depletion, muscle weakness, and respiratory failure. Disease progression varies from infantile-onset rapid decline to slower adult-onset forms. The market is driven by gene therapy advancements and unmet needs, with key players like Modis Therapeutics, Ultragenyx, and ReGenX Biosciences pioneering treatments.
Explore the TK2D Market Landscape:
https://www.delveinsight.com/infographics/thymidine-kinase-2-deficiency-tk2d-market?utm_source=infographics&utm_medium=promotion&utm_campaign=kkpr
